首页> 外文期刊>Indian drugs >DOMESTIC APIs AND INTERMEDIATES-THE NEED OF THE HOUR
【24h】

DOMESTIC APIs AND INTERMEDIATES-THE NEED OF THE HOUR

机译:国内API和中间体 - 需要时的需要

获取原文
获取原文并翻译 | 示例
       

摘要

As I write this editorial, some of the current events that we are faced with in the pharmaceutical industry in INDIA, bears greatly on my mind. The exponential rise in the cost of a large number of APIs is causing great anguish and stress for formulation manufacturers. The rise in the cost of these APIs or their intermediates sourced from China is attributed as the reason for this increase. As a result, a number of essential drugs are experiencing shortages in various parts of our country. The year 2015 was declared as the year of ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) by the Department of Pharmaceuticals. While we still await the announcement of concessions based on the multiple representations made to the various ministries, the current crisis maybe a god sent opportunity for the domestic API manufacturers to restart manufacturing a number of the APIs that were uneconomical due to price pressures from APIs produced in China.
机译:正如我写这篇社论,我们在印度制药行业面临的一些目前的事件大大忍受了我的脑海。 大量API成本的指数上升导致配方制造商的痛苦和压力很大。 这些API的成本或从中国采购的中间体的增加归因于此增加的原因。 因此,许多基本药物在我国各地区都会经历短缺。 2015年由药品部宣布为活性药物成分(API)的年份。 虽然我们仍在等待基于各部委的多个代表的特许权宣布,但目前的危机可能是一个上帝为国内API制造商发出的机会,以重新制造一些由于API所产生的价格压力而不经济的API。 在中国。

著录项

  • 来源
    《Indian drugs》 |2018年第9期|共2页
  • 作者

    George Patani;

  • 作者单位

    Associate Editor Indian Drugs;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

  • 入库时间 2022-08-20 01:46:13

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号